SCHEMBL6788075

SCHEMBL6788075

N#CCn1cc2ccc(NC(=O)c3ccccc3NCc3ccc(=O)[nH]c3)cc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 4/20 0.40
KDR P35968 4/20 0.40
KIT P10721 10/20 0.39
BRAF P15056 8/20 0.39
RXFP1 Q9HBX9 2/20 0.38
ABL1 P00519 2/20 0.38
CSF1R P07333 2/20 0.38
PDGFRB P09619 2/20 0.38
FLT4 P35916 2/20 0.38
EGFR P00533 1/20 0.38
NOTUM Q6P988 1/20 0.37
KMT2A Q03164 1/20 0.36
IGF1R P08069 1/20 0.36
FGFR1 P11362 1/20 0.36
TEK Q02763 1/20 0.36
MLLT1 Q03111 1/20 0.36
JAK2 O60674 2/20 0.35
JAK1 P23458 2/20 0.35
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866933 0.83 KIT (0.47) FLT1KDRKITBRAFABL1
SCHEMBL6785680 0.82 MLLT1 (0.42) FLT1KDRKITBRAFRXFP1
SCHEMBL3872732 0.76 KIT (0.47) FLT1KDRKITBRAFABL1
SCHEMBL6786372 0.75 KDR (0.57) FLT1KDRJAK2JAK1
SCHEMBL5900542 0.72 RXFP1 (0.52) FLT1KDRKITBRAFRXFP1
SCHEMBL3872701 0.71 NOTUM (0.49) FLT1KDRKITBRAFNOTUM
SCHEMBL5900863 0.70 RXFP1 (0.53) FLT1KDRKITBRAFRXFP1
SCHEMBL14483974 0.70 ABCG2 (0.56) KMT2A
SCHEMBL5901817 0.70 RXFP1 (0.50) FLT1KDRKITBRAFRXFP1
SCHEMBL1037818 0.70 RXFP1 (0.75) FLT1KDRKITRXFP1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040039019-A1 Selected anthranilaminde pyridinamides and their use as pharmaceutical agents SCHERING AG (DE) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039019-A1 Selected anthranilaminde pyridinamides and their use as pharmaceutical agents KDR, FLT1, FLT4 FLT1 2/4885KDR 1/4885KIT 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.